|
Obesity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hemostatic abnormalities including TAFI alterations represent a link between obesity and vascular thrombosis.
|
16959692 |
2006 |
|
Amenorrhea
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).
|
16167916 |
2005 |
|
Postpartum Amenorrhea
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
|
16167916 |
2005 |
|
Experimental Autoimmune Encephalomyelitis
|
0.200 |
Biomarker
|
disease |
RGD |
Minocycline effects on the cerebrospinal fluid proteome of experimental autoimmune encephalomyelitis rats.
|
22768796 |
2012 |
|
Multiple Organ Failure
|
0.200 |
Biomarker
|
phenotype |
RGD |
EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
|
19325462 |
2009 |
|
Chemical and Drug Induced Liver Injury
|
0.200 |
Biomarker
|
disease |
RGD |
A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture.
|
19386599 |
2009 |
|
Bacteremia
|
0.200 |
Biomarker
|
disease |
RGD |
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
|
17911187 |
2007 |
|
Sepsis
|
0.200 |
Biomarker
|
disease |
RGD |
Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.
|
15497025 |
2004 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
|
29194929 |
2018 |
|
Cerebrovascular accident
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The dose-response curve showed that, as a whole, with the increase of TAFI levels, the relative risk of stroke first increased and then decreased (p=0.0127).
|
28890533 |
2017 |
|
Cerebrovascular accident
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke.
|
18986391 |
2008 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
AP showed associations with all 4 major subtypes of ischemic stroke and intact TAFI to large vessel disease and cryptogenic stroke.
|
17272741 |
2007 |
|
Cerebrovascular accident
|
0.060 |
AlteredExpression
|
group |
LHGDN |
AP showed associations with all 4 major subtypes of ischemic stroke and intact TAFI to large vessel disease and cryptogenic stroke.
|
17272741 |
2007 |
|
Cerebrovascular accident
|
0.060 |
AlteredExpression
|
group |
LHGDN |
Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
|
17473579 |
2007 |
|
Cerebrovascular accident
|
0.060 |
AlteredExpression
|
group |
BEFREE |
This indicates that increased functional TAFI levels after stroke are not caused by an acute phase reaction.
|
16092924 |
2005 |
|
Thrombophilia
|
0.050 |
Biomarker
|
disease |
BEFREE |
The authors discuss the similarities and differences between TIC and MAC, and propose a mechanism for the hypercoagulable state of MAC that revolves around the thrombomodulin-thrombin complex as it switches between activating the protein C anticoagulation pathway or the thrombin activatable fibrinolysis inhibitor coagulation pathway.
|
31108555 |
2019 |
|
Ischemic stroke
|
0.050 |
Biomarker
|
disease |
BEFREE |
Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
|
29194929 |
2018 |
|
Thrombophilia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
TAFI serves as a link between two limbs of hemostasis, with its higher levels promoting inhibition of fibrinolytic system and thus promoting a hypercoagulable state.
|
27487812 |
2017 |
|
Ischemic stroke
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Similarly, in general, with the increase of TAFI levels, the curve showed that the relative risk of ischemic stroke first increased and then decreased (p=0.0110).
|
28890533 |
2017 |
|
Thrombophilia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
High level of TAFI antigen in attack-free period of FMF disease shows ongoing subclinical inflammation and hypercoagulability.
|
24580410 |
2014 |
|
Ischemic stroke
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
High functional CPB2 levels have been found to be associated with an increased risk for ischemic stroke.
|
18986391 |
2008 |
|
Thrombophilia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thrombin-activatable fibrinolysis inhibitor (TAFI) may contribute to a hypercoagulable state, and therefore we were interested in the role of TAFI in SVT.
|
17264944 |
2007 |
|
Ischemic stroke
|
0.050 |
Biomarker
|
disease |
BEFREE |
AP showed associations with all 4 major subtypes of ischemic stroke and intact TAFI to large vessel disease and cryptogenic stroke.
|
17272741 |
2007 |